PHATHOM PHARMACEUTICALS, INC. (PHAT) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $164.59M; Long-term DebtUSD $164.59M; Long-term Debt, GrossUSD $175.00M.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $163.68M; Long-term DebtUSD $163.68M; Long-term Debt, GrossUSD $175.00M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $209.09M; Long-term DebtUSD $209.09M; Long-term Debt, GrossUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-term Debt, GrossUSD $200.00M.
PHATHOM PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount USD | Convertible Notes Payable, Current USD | Notes Payable, Related Parties, Current USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $164.59M | $164.59M | $175.00M | $10.41M | (m) | (m) |
| 2026-03-31 | $0.00 | $163.68M | $163.68M | $175.00M | $11.32M | (m) | (m) |
| 2025-12-31 | $0.00 | $209.09M | $209.09M | (m) | $7.41M | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $200.00M | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $207.09M | $207.09M | $200.00M | $8.22M | (m) | (m) |
| 2025-06-30 | $0.00 | $205.14M | $205.14M | $200.00M | $8.99M | (m) | (m) |
| 2025-03-31 | $0.00 | $203.25M | $203.25M | $200.00M | $9.73M | (m) | (m) |
| 2024-12-31 | $0.00 | $201.41M | $201.41M | (m) | $10.42M | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $200.00M | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $175.73M | $175.73M | $175.00M | $10.05M | (m) | (m) |
| 2024-06-30 | $0.00 | $174.42M | $174.42M | $175.00M | $10.34M | (m) | (m) |
| 2024-03-31 | $0.00 | $149.02M | $149.02M | $150.00M | $9.84M | (m) | (m) |
| 2023-12-31 | $0.00 | $137.84M | $137.84M | (m) | $10.21M | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $140.00M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $99.26M | $99.26M | $100.00M | $7.90M | (m) | (m) |
| 2023-06-30 | (m) | $97.81M | $97.81M | $100.00M | $8.44M | (m) | (m) |
| 2023-03-31 | (m) | $96.64M | $96.64M | $100.00M | $8.71M | (m) | (m) |
| 2022-12-31 | $0.00 | $95.26M | $95.26M | (m) | $9.21M | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $93.88M | $93.88M | $100.00M | $9.71M | (m) | (m) |
| 2022-06-30 | (m) | $92.43M | $92.43M | $100.00M | $10.27M | (m) | (m) |
| 2022-03-31 | (m) | $91.04M | $91.04M | $100.00M | $10.80M | (m) | (m) |
| 2021-12-31 | (m) | $89.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $89.67M | $100.00M | $11.32M | (m) | (m) |
| 2021-09-30 | (m) | $88.31M | $88.31M | $100.00M | $11.82M | (m) | (m) |
| 2021-06-30 | $10.35M | $37.34M | $47.69M | $50.00M | $2.31M | (m) | (m) |
| 2021-03-31 | $11.77M | $35.59M | $47.35M | $50.00M | $2.65M | (m) | (m) |
| 2020-12-31 | $7.35M | $39.63M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $46.99M | $50.00M | $3.01M | (m) | (m) |
| 2020-09-30 | $5.56M | $41.06M | $46.62M | $50.00M | $3.38M | (m) | (m) |
| 2020-06-30 | $1.39M | $44.87M | $46.26M | $50.00M | $3.74M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $45.91M | $50.00M | $4.09M | (m) | (m) |
| 2019-12-31 | (m) | $22.78M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $22.78M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | $25.00M | $2.22M | (m) | $0.00 |
| 2019-09-30 | (m) | (m) | $22.61M | $25.00M | $2.39M | $95.23M | $21.10M |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $1.95M | $1.95M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |